Sayfa yüklenirken bir hata oluştu.
Teknik ekibimiz bilgilendirildi, ancak sorunun devam etmesi durumunda lütfen e-posta destek widget ile bize ulaşın.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM EBITDA Multiple | 5,3x - 5,8x | 5,5x |
| Selected Fwd EBITDA Multiple | 5,1x - 5,6x | 5,3x |
| Fair Value | ₩15.292 - ₩17.151 | ₩16.222 |
| Upside | 23,3% - 38,3% | 30,8% |
| Benchmarks | Ticker | Full Ticker |
| DongKoo Bio & Pharma Co., Ltd. | A006620 | KOSDAQ:A006620 |
| Sinsin Pharmaceutical Co., Ltd | A002800 | KOSDAQ:A002800 |
| KUKJEON PHARMACEUTICAL Co., Ltd | A307750 | KOSDAQ:A307750 |
| Kyung Dong Pharmaceutical Co., Ltd. | A011040 | KOSDAQ:A011040 |
| Huons Co., Ltd. | A243070 | KOSDAQ:A243070 |
| JW Lifescience Corporation | A234080 | KOSE:A234080 |
| - | - | - |
| Select LTM EBITDA Multiple | |||||||
| Benchmark Companies | |||||||
| A006620 | A002800 | A307750 | A011040 | A243070 | A234080 | ||
| KOSDAQ:A006620 | KOSDAQ:A002800 | KOSDAQ:A307750 | KOSDAQ:A011040 | KOSDAQ:A243070 | KOSE:A234080 | ||
| Historical EBITDA Growth | |||||||
| 5Y CAGR | NM- | 26.1% | NM- | -23.9% | 0.8% | 4.5% | |
| 3Y CAGR | 14.8% | 68.5% | -8.8% | -29.3% | 1.4% | 7.4% | |
| Latest Twelve Months | -18.6% | 23.0% | -55.1% | 161.6% | -15.6% | 13.7% | |
| Historical EBITDA Profit Margin | |||||||
| 5 Year Average Margin | 9.3% | 6.1% | 6.0% | 6.1% | 13.2% | 24.0% | |
| Prior Fiscal Year | 9.6% | 9.7% | 7.9% | -11.7% | 13.4% | 22.4% | |
| Latest Fiscal Year | 8.0% | 10.5% | 4.0% | 4.1% | 10.3% | 23.2% | |
| Latest Twelve Months | 7.5% | 11.1% | 3.1% | 5.1% | 10.7% | 21.6% | |
| Current Trading Multiples | |||||||
| EV / LTM Revenue | 0.66x | 1.21x | 1.51x | 0.50x | 0.67x | 0.95x | |
| EV / LTM EBITDA | 8.8x | 11.0x | 49.3x | 10.0x | 6.2x | 4.4x | |
| EV / LTM EBIT | 15.7x | 17.2x | -182.2x | 20.0x | 9.4x | 6.3x | |
| Low | Mid | High | |||||
| Benchmark EV / LTM EBITDA | 6.2x | 10.0x | 49.3x | ||||
| Historical EV / LTM EBITDA | 3.1x | 5.5x | 7.5x | ||||
| Selected EV / LTM EBITDA | 5.3x | 5.5x | 5.8x | ||||
| (x) LTM EBITDA | 52,552 | 52,552 | 52,552 | ||||
| (=) Implied Enterprise Value | 276,599 | 291,156 | 305,714 | ||||
| (-) Non-shareholder Claims * | (36,772) | (36,772) | (36,772) | ||||
| (=) Equity Value | 239,826 | 254,384 | 268,942 | ||||
| (/) Shares Outstanding | 15.5 | 15.5 | 15.5 | ||||
| Implied Value Range | 15,488.09 | 16,428.25 | 17,368.40 | ||||
| FX Rate: KRW/KRW | 1.0 | 1.0 | 1.0 | Market Price | |||
| Implied Value Range (Trading Cur) | 15,488.09 | 16,428.25 | 17,368.40 | 12,400.00 | |||
| Upside / (Downside) | 24.9% | 32.5% | 40.1% | ||||
| Equity Waterfall | |||||||
| Benchmark Companies | |||||||
| (in millions) | A006620 | A002800 | A307750 | A011040 | A243070 | A234080 | |
| Enterprise Value | 161,150 | 130,756 | 210,555 | 98,020 | 392,171 | 228,781 | |
| (+) Cash & Short Term Investments | 39,651 | 959 | 38,582 | 32,582 | 67,174 | 26,465 | |
| (+) Investments & Other | 50,883 | 7,442 | 5,185 | 68,323 | 56,304 | 2,062 | |
| (-) Debt | (96,418) | (45,717) | (57,868) | (36,205) | (169,395) | (65,299) | |
| (-) Other Liabilities | (44) | 315 | 161 | (261) | (4,669) | 0 | |
| (-) Preferred Stock | 0 | 0 | 0 | 0 | 0 | 0 | |
| (-) Other | 0 | 0 | 0 | 0 | 0 | 0 | |
| Value of Common Equity | 155,222 | 93,754 | 196,616 | 162,459 | 341,585 | 192,008 | |
| (/) Shares Outstanding | 27.0 | 15.2 | 50.0 | 26.9 | 11.7 | 15.5 | |
| Implied Stock Price | 5,740.00 | 6,180.00 | 3,935.00 | 6,030.00 | 29,200.00 | 12,400.00 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |
| Implied Stock Price (Trading Cur) | 5,740.00 | 6,180.00 | 3,935.00 | 6,030.00 | 29,200.00 | 12,400.00 | |
| Trading Currency | KRW | KRW | KRW | KRW | KRW | KRW | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | |